The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics

• ClinicalTrials.gov Identifier: NCT00625989
• Recruitment Status: Completed
• First Posted: February 29, 2008
• Results First Posted: May 15, 2015
• Last Update Posted: May 21, 2018
• Sponsor: Hamilton Health Sciences Corporation
• Information provided by (Responsible Party): McMaster University ( Hamilton Health Sciences Corporation )

Study Description

Brief Summary:

Summary:

A picture is emerging of dendritic cells migrating through the blood to the airways following allergen inhalation in atopic asthmatics. Although the Koh and McCarthy articles present novel findings, both do not provide a comprehensive view of sputum DCs following allergen challenge. Therefore, the proposed study will examine the kinetics of mDCs and pDCs in the induced sputum of atopic asthmatics following inhalation of allergen.

Hypothesis:

Following allergen challenge, sputum myeloid and plasmacytoid DCs will migrate into the airway lumen in atopic asthmatics during the timeframe of the late asthmatic response.

Objective:

The objective of this study is to examine the kinetics of dendritic cells in induced sputum following allergen challenge in atopic asthmatic subjects.

Condition or disease	Intervention/treatment	Phase
Asthma	Drug: Aeroallergen	Early Phase 1

Detailed Description:

Subjects will be put through two study periods. Each study period will consist of four visits and will be separated by 2-4 weeks. On the first visit, subjects will undergo screening procedures, including complete history and physical examination. In addition, methacholine inhalation challenge and skin-prick testing will be preformed to assess airway hyper-responsiveness and determine atopic status respectively. Lastly, sputum will be induced before challenge (0 hrs) and peripheral blood will be collected. On the second visit, subjects will inhale diluent or allergen and sputum will be collected 7 hours following inhalation challenge. Next, on the third visit, subjects will return 24 hours following inhalation challenge and sputum will be induced. On the final visit, subjects will return 72 hours following inhalation challenge and sputum will be collected, along with peripheral blood.

Before the next study period begins, there will be a washout period of 2-4 weeks. On the first visit of the second study period, a methacholine challenge will be performed to ensure the return of PC20 to within one doubling dose of baseline values. Also, sputum will be induced before challenge (0hrs) and peripheral blood will be collected. On the second visit, subjects will inhale diluent or allergen and sputum will be collected 7hrs following inhalation challenge. Next, on the third visit, subjects will return 24 hours following inhalation challenge and sputum will be induced. On the final visit, subjects will return 72 hours following inhalation challenge and sputum will be collected, along with peripheral blood.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 12 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics
• Study Start Date: February 2008
• Actual Primary Completion Date: November 2008
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Diluent; Inhalation challenge preformed with diluent.	Drug: Aeroallergen
Active Comparator: Allergen; Inhalation challenge preformed with allergen.	Drug: Aeroallergen

Outcome Measures

Primary Outcome Measures :

1. The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells [ Time Frame: 24 hrs ]
   Flow-cytometric acquisitions were used to determine the percentage of each type of mononuclear cell. These percentages were multiplied by the number of sputum mononuclear cells calculated by using total and differential cell counts of the sputum sample.
2. The Primary Outcome Measure for This Study is the Number of Sputum Plasmacytoid Dendritic Cells [ Time Frame: 24 hrs ]
   Flow-cytometric acquisitions were used to determine the percentage of each type of mononuclear cell. These percentages were multiplied by the number of sputum mononuclear cells calculated by using total and differential cell counts of the sputum sample.

Secondary Outcome Measures :

1. The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant. [ Time Frame: Before inhalation (0hrs) ]
2. The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant [ Time Frame: 7 hrs ]
3. The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant [ Time Frame: 24 hrs ]
4. The Secondary Outcome Measure is the Level of Specific Chemokines Released in the Sputum Supernatant [ Time Frame: 72 hrs ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Mild atopic asthmatics, presently well controlled on ß2-agonists.
• Non-smokers.
• Baseline FEV1 more than 70% of predicted normal.

Exclusion Criteria:

• Airway infection during the last 4 weeks.
• Exacerbation during the last 4 weeks.
• Inhaled or oral steroids during the last 4 weeks.
• Antihistamines during the last 48 hours.
• Asthma medication other than inhaled and/or oral ß2-agonists during the last 4 weeks.
• Pregnant women.

Contacts and Locations

Locations

Canada, Ontario

McMaster University

Hamilton, Ontario, Canada, L8N 3Z5

Sponsors and Collaborators

Hamilton Health Sciences Corporation

Investigators

• Principal Investigator: Paul O'Byrne, MD; McMaster University
• Principal Investigator: Gail Gauvreau, PhD; McMaster University

More Information

• Responsible Party: Hamilton Health Sciences Corporation
• ClinicalTrials.gov Identifier: NCT00625989
• Other Study ID Numbers: sputdend08; BDUA2008
• First Posted: February 29, 2008
• Results First Posted: May 15, 2015
• Last Update Posted: May 21, 2018
• Last Verified: April 2015

Keywords provided by McMaster University ( Hamilton Health Sciences Corporation ):

asthma; atopy; allergen challenge; sputum myeloid and plasmacytoid dendritic cells

Additional relevant MeSH terms:

Asthma; Respiratory Aspiration; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Respiration Disorders; Pathologic Processes